Hyperkinetic circulation and decreased sensitivity to vasoconstrictors following portacaval shunt in the rat. Effects of chronic nitric oxide inhibition

Journal of Hepatology

Volumn 31, Issue 4, 1999, Pages 719-724

  Bandi, Juan Carlos ^b   Fernández, Mercedes ^b   Bernadich, Cristina ^b   De Lacy, Antonio M ^b   García Pagán, Juan Carlos ^b   Bosch, Jaime ^a   Rodés, Juan ^b  

^a Hepat Hemodynamic Lab Liver U   (Spain)

^b NONE

Author keywords

Dose response relationship; Drug effects; Hemodynamics; Splanchnic circulation; adrenergic agonist

Indexed keywords

ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; METHOXAMINE; N(G) NITRO DEXTRO ARGININE METHYL ESTER; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; VASOCONSTRICTOR AGENT;

ADOLESCENT; ARTERIAL PRESSURE; ARTICLE; BLOOD VESSEL REACTIVITY; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; HEART OUTPUT; MALE; NONHUMAN; PORTOCAVAL SHUNT; PRIORITY JOURNAL; RAT; SPLANCHNIC BLOOD FLOW; SUPERIOR MESENTERIC ARTERY; VASCULAR RESISTANCE;

EID: 0344117716     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8278(99)80353-5     Document Type: Article

References (25)

1. More N, Lobosotomayor G, Basse-Cathalinat B, Bedin C, Balabaud C. Splanchnic arterial blood flow in rats with portacaval shunt. Am J Physiol. 246:1984;G331-G334.
2. Kravetz D, Arderiu M, Bosch J, Fuster J, Visa J, Casamitjana R, et al. Hyperglucagonemia and hyperkinetic circulation after portacaval shunt in the rat. Am J Physiol. 252:1987;G257-G261.
3. Lee SS, Johansen K, Lebrec D. Circulatory changes induced by portal venous diversion and mesenteric hypertension in rats. Hepatology. 15:1992;117-121.
4. Wu Z-Y, Benoit JN. Vascular NE responsiveness in portal hypertension: role of portal pressure and portosystemic shunting. Am J Physiol. 266:1994;H1162-H1168.
5. Bosch J, Pizcueta P, Feu F, Fernández M, García-Pagán JC. Pathophysiology of portal hypertension. Gastroenterol Clin North Am. 21:1992;1-13.
6. Pizcueta MP, Piqué JM, Bosch J, Whittle BJR, Moncada S. Effects of inhibiting nitric oxide biosynthesis on the systemic and splanchnic circulation of rats with portal hypertension. Br J Pharmacol. 105:1992;184-190.
7. Clària J, Jiménez W, Ros J, Asbert M, Castro A, Arroyo V, et al. Pathogenesis of arterial hypotension in cirrhotic rats with ascites: role of endogenous nitric oxide. Hepatology. 15:1992;343-349.
8. Pizcueta P, Piqué JM, Fernández M, Bosch J, Rodés J, Whittle BJR, et al. Modulation of the hyperdynamic circulation of cirrhotic rats by nitric oxide inhibition. Gastroenterology. 103:1992;1909-1915.
9. Sieber CC, Lopez-Talavera JC, Groszmann RJ. Role of nitric oxide in the in vitro splanchnic vascular hyporeactivity in ascitic cirrhotic rats. Gastroenterology. 104:1993;1750-1754.
10. Groszmann RJ. Hyperdynamic circulation of liver disease 40 years later: pathophysiology and clinical consequences. Hepatology. 20:1994;1359-1363.
11. Benoit JN, Barrowman JA, Harper SL, Kvietys PR, Granger DN. Role of humoral factors in the intestinal hyperaemia associated with chronic portal hypertension. Am J Physiol. 247:1984;G486-G493.
12. Kravetz D, Bosch J, Arderiu M, Pizcueta MP, Casamitjana R, F Rivera, et al. Effects of somatostatin on splanchnic hemodynamics and plasma glucagon in portal hypertensive rats. Am J Physiol. 254:1988;G322-G328.
13. Benoit JN, Zimmerman B, Premen AJ, Go VLW, Granger DN. Role of glucagon in splanchnic hyperaemia of chronic portal hypertension. Am J Physiol. 251:1986;G674-G677.
14. Fernandez M, Garcia-Pagan JC, Casadevall M, Mourelle MI, Pique JM, Bosch J, et al. Acute and chronic cyclooxygenase blockage in portal-hypertensive rats: influence in nitric oxide biosynthesis. Gastroenterology. 110:1996;1529-1535.
15. Sitzmann JV, Li SS, Lin PW. Prostacyclin mediates splanchnic vascular response to norepinephrine in portal hypertension. J Surg Res. 47:1989;208-211.
16. Pizcueta MP, Casamitjana R, Bosch J, Rodés J. Decreased systemic vascular sensitivity to norepinephrine in portal hypertensive rats. Role of hyperglucagonism. Am J Physiol. 258:1990;G191-G195.
17. Sieber CC, Groszmann RJ. Nitric oxide mediates hyporeactivity to vasopressors in mesenteric vassels of portal hypertensive rats. Gastroenterology. 103:1992;235-239.
18. Lee SH, Fisher B. Portacaval shunt in the rat. Surgery. 50:1961;668-672.
19. García-Pagán JC, Fernández M, Bernadich C, Pizcueta P, Piqué JM, Bosch J, et al. Effects of continued NO inhibition on portal hypertensive syndrome after portal vein stenosis in rat. Am J Physiol. 267:1994;G984-G990.
20. Bernadich C, Fernández M, Bandi JC, Bosch J, Rodés J. Mechanical pumping of portal blood to the liver: hemodynamic effects of a new experimental treatment for portal hypertension. J Hepatol. 25:1996;98-105.
21. Pizcueta MP, García-Pagán JC, Fernández M, Casamitjana R, Bosch J, Rodés J. Glucagon hinders the effects of somatostatin on portal hypertension. A study in rats with partial portal vein ligation. Gastroenterology. 101:1991;1710-1715.
22. Kiel JW, Pitts V, Benoit JN, Granger DN, Shepherd AP. Reduced vascular sensitivity to norepinephrine in portal-hypertensive rats. Am J Physiol. 248:1985;G192-G195.
23. Lee FY, Albillos A, Colombato L, Groszmann RJ. The role of nitric oxide in the vascular hyporesponsiveness to methoxamine in portal hypertensive rats. Hepatology. 16:1992;1043-1048.
24. ω-Nitro-L-arginine administration corrects peripheral vasodilation and systemic capillary hypotension and ameliorates plasma volume expansion and sodium retention in portal hypertensive rats. Hepatology. 17:1993;84-90.
25. Bernadich C, Bandi JC, Piera C, Bosch J, Rodés J. Circulatory effects of graded diversion of portal blood flow to the systemic circulation in rats: role of nitric oxide. Hepatology. 26:1997;262-267.